Compilation : summary of guidance issued to the NHS in England and Wales. Issue 7. October 2003

360 Pages·2003·20.1 MB·English

by  Great Britain. National Health Service. National Institute for Clinical Excellence, author

National Institute for
Clinical Excellence
Compilation
Summary of Guidance issued to
the NHS in England and Wales
Issue7
(@YKea) oil- 1 4010):
j
e
l
u
e
J
O‘
ep
sa
Ue
p
!
i

e
pb
a
e
i
is
ni
jp|
d
1 ne
a q
nJ
sop
s i
iUn
Oo
uEy
oss

N!
eOs
lqu
i n
u
d p
wUe
oas
g o
u
|d
!
J0
o9
s
¢Uiy|
9Oj

pgU
uoO
eu
es
zp}
giU
' J a ns
S OJ 2U seb WS
H a bp
N 22 Ja edenje]
N} I ssS
I} XJ Uo i au
Z F J}}
S a
U oAp
] /e e Joue
[EIIUWA Ue u Sst
UOII/DLVd S| eEY usAi
ZE da 16FOIneu
N s 4Ne
|

MONA
22503547917
Compilation
Summary of Guidance issued to
the NHS in England and Wales
Issue /
October 2003
The Guidance in this document is written in the following context
This Guidance represents the view of the Institute which was arrived at after careful
consideration of the available evidence. Health professionals are expected to take it
fully into account when exercising their clinical judgment. This Guidance does not,
however, override the individual responsibility of health professionals to make appro-
priate decisions in the circumstances of the individual patient, in consultation with
the patient and/or guardian or carer.
National Institute for Clinical Excellence
MidCity Place
71 High Holborn
London
WC1V 6NA
Web: www.nice.org.uk
ISSN: 1473-3730
Published by the National Institute for Clinical Excellence, October 2003
Order ref: NO339
© National Institute for Clinical Excellence 2003. All rights reserved. This material
may be freely reproduced for educational and not for profit purposes within the
NHS. No reproduction by or for commercial organisations is permitted without the
express written permission of the Institute.
For permissions contact:
Corporate Affairs Director
National Institute for Clinical Excellence
MidCity Place, 71 High Holborn, London WC1V 6NA.
Contents
Acknowledgements 5
Introduction 6
New Guidance /7
How to use this document 9
Obtaining further information 10
Guidance issued
eBehavioural 11
eCancer 15
e Cardiovascular 31
e Central nervous system 75
e Dental, oral and facial 79
eEar, nose andthroat 82
e Endocrine and metabolic 85
eEye 119
¢ Gastrointestinal 121
e Gynaecology, pregnancy and birth 126
° Infections and infectious diseases 174
e|njuries and accidents 192
° Mental health 222
e Musculo-skeletal 251
e Nutritional disorders and weight control 260
e Renal and urinary 265
© Respiratory 269
e Skin disorders and wounds 272
e Miscellaneous 284
Appendices
Appendix A: Forward work plans 303
Appendix B: Appraisals Committee 311
Appendix C: Guideline Review Panels 316
Appendix D: Interventional Procedures Advisory
Committee 320
Appendix E: Technology Appraisal Process—Summary 322
Appendix F: Clinical Guidelines Development
Process—Summary 325
Appendix G: Interventional Procedures Process —
Summary 329
Appendix H: Ordering information 332
Index 350
Acknowledgements
The development of NICE guidance relies on the time and
commitment of those with whom the Institute works.
The Institute wishes to acknowledge the contribution of the
members of the Appraisal Committee, the Guidelines Advisory
Committee, the Partners Council, the academic teams, the
national patient/carer organisations and individual
manufacturers.
In addition, the Institute acknowledges the support, help,
advice and commitment of a wide range of health
professionals and their representative groups, including the
Royal Colleges, numerous professional associations and
societies and of course the wider NHS.
Introduction
The National Institute for Clinical Excellence (the Institute) is
part of the NHS. It is a Special Health Authority and it provides
guidance for the NHS and patients on medicines, medical
equipment and clinical procedures based on evidence of both
clinical and cost effectiveness.
The Institute has been described as a virtual network. It has 60
full time employees and works with patient/carer organisations,
NHS R&D manufacturers, doctors, nurses, pharmacists,
academics and other health professionals in England and Wales
to prepare its guidance.
Full details on the Institute and its work are available on the
NICE web site (www.nice.org.uk).
New Guidance
@ Tare) Csi lel) acest
Antenatal care: routine care for the healthy pregnant woman
127
Chronic heart failure - Management of chronic heart failure in
adults in primary and secondary care 32
Infection control — Prevention of healthcare-associated
infection in primary and community care 175
Preoperative tests — The use of routine preoperative tests for
elective surgery 285
Pressure ulcer prevention — Pressure ulcer risk assessment and
prevention, including the use of pressure-relieving devices
(beds, mattresses and overlays) for the prevention of
pressure ulcers in primary and secondary care 274
Triage, assessment, investigation and early management of
head injury in infants, children and adults 193
Interventional Procedures —
Balloon thermal endometrial ablation 151
Coblation tonsillectomy 83
Coil embolisation of ruptured intracranial aneurysms 62
Islet cell transplantation 91
Laparoscopic radical prostatectomy 20
Microwave endometrial ablation 170
Minimally invasive placement of pectus bar 258
Percutaneous vertebroplasty 259
Radiofrequency ablation of hepatocellular carcinoma 24
Radiofrequency ablation of varicose veins 73
Sacral nerve stimulation for faecal incontinence 125
Sacral nerve stimulation for urge incontinence 267
Stent-graft placement in abdominal aortic aneurysm 73
Stereotactic radiosurgery for trigeminal neuralgia using the
gamma knife 80
Transurethral electrovapourisation of prostate (TEVAP) 268
Transurethral radiofrequency needle ablation of prostate
(TUNA) 268
Uterine artery embolisation for fibroids 172
Technology Appraisals
Capecitabine for the treatment of locally advanced or
metastatic breast cancer 16
Capecitabine and tegafur with uracil for metastatic colorectal
cancer 16
Glitazones for the treatment of type 2 diabetes 87
Human growth hormone (somatropin) in adults with growth
hormone deficiency 88
Olanzapine and valproate semisodium in the treatment of
acute mania associated with bipolar! 250
Oseltamivir and amantadine for the prophylaxis of influenza
188
Photodynamic therapy for age-related macular degeneration
120
Rituximab for aggressive non Hodgkin’s lymphoma 25